REFERENCES
- Calonge M. Classification of ocular atopic/allergic disorders and conditions: An unsolved problem. Acta Ophthalmol Scand Suppl 1999; 228: 10–13
- Schalnus R. Topical nonsteroidal anti-inflammatory therapy in ophthalmology. Ophthalmol 2003; 217(2)89–98
- Uchio E. Possibility of non-steroidal treatment in allergic conjunctival diseases. Allerg Internat 2004; 53(4)315–319
- Helleboid L. Treatment of allergic conjunctivitis and keratoconjunctivitis summary. Revue Francaise d'Allergologie et d'Immunologie Clinique 2004; 44(1)71–75
- Hingorani M, Lightman S. Therapeutic options in ocular allergic disease. Drugs 1995; 50(2)208–221
- Bielory L. Ocular allergy guidelines: a practical treatment algorithm. Drugs 2002; 62(11)1611–1634
- Al Yusuf N SH, Al Alawi E K. The effect of diclofenac sodium on allergic conjunctivitis. J Bahrain Med Soc 1999; 11(2)26–31
- Avunduk A M, Avunduk M C, Varnell E D, Kaufman H E. The comparison of efficacies of topical corticosteroids and nonsteroidal anti-inflammatory drops on dry eye patients:A clinical and immunocytochemical study.[see comment]. Am J Ophthalmol 2003; 136(4)593–602
- D'Angelo G, Lambiase A, Cortes M, Sgrulletta R, Pasqualetti R, Lamagna A, Bonini S. Preservative-free diclofenac sodium 0.1% for vernal keratoconjunctivitis. Graefes Arch Clin Exper Ophthalmol 2003; 241(3)192–195
- Deschenes J, Discepola M, Abelson M. Comparative evaluation of olopatadine ophthalmic solution (0.1%) versus ketorolac ophthalmic solution (0.5%) using the provocative antigen challenge model. Acta OphthalmolScandSuppl 1999; 228: 47–52
- Discepola M, Deschenes J, Abelson M. Comparison of the topical ocular antiallergic efficacy of emedastine 0.05% ophthalmic solution to ketorolac 0.5% ophthalmic solution in a clinical model of allergic conjunctivitis. Acta Ophthalmol ScandiSuppl 1999; 228: 43–46
- James I G, Campbell L M, Harrison J M, Fell P J, Ellers–Lenz B, Petzold U. Comparison of the efficacy and tolerability of topically administered azelastine, sodium cromoglycate and placebo in the treatment of seasonal allergic conjunctivitis and rhino-conjunctivitis. Curr Med Res Opin 2003; 19(4)313–320
- Leonardi A, Busato F, Fregona I, Plebani M, Secchi A G. Anti-inflammatory and antiallergic effects of ketorolac tromethamine in the conjunctival provocation model. Br J Ophthalmol 2000; 84(11)1228–1232
- Miyake-Kashima M, Takano Y, Tanaka M, Satake Y, Kawakita T, Dogru M, Asano-Kato N, Fukagawa K, Fujishima H. Comparison of 0.1% bromfenac sodium and 0.1% pemirolast potassium for the treatment of allergic conjunctivitis. Japan J Ophthalmol 2004; 48(6)587–590
- Notivol R, Martinez M, Bergamini M V. Treatment of chronic nonbacterial conjunctivitis with a cyclo-oxygenase inhibitor or a corticosteroid. Pranoprofen Study Group. Am J Ophthalmol 1994; 117(5)651–656
- Shulman D G, Amdahl L, Washington C, Graves A. A combined analysis of two studies assessing the ocular comfort of antiallergy ophthalmic agents. Clin Therapeut. 2003; 25(4)1096–1106
- Tauber J, Raizman M B, Ostrov C S, Laibovitz R A, Abelson M B, Betts J G, Koester J M, Gill D, Schaich L. A multicenter comparison of the ocular efficacy and safety of diclofenac 0.1% solution with that of ketorolac 0.5% solution in patients with acute seasonal allergic conjunctivitis. J Ocular Pharmacol Therapeu 1998; 14(2)137–145
- Ciprandi G, Cerqueti P M, Sacca S, Ciurlo G, Tosca M A, Canonica G W. Non-steroidal treatment of pollen-induced conjunctivitis: Comparison of different pharmacological protocols. Allergy 1991; 46(5)393–395
- Ballas Z, Blumenthal M, Tinkelman D G, Kriz R, Rupp G. Clinical evaluation of ketorolac tromethamine 0.5% ophthalmic solution for the treatment of seasonal allergic conjunctivitis. Surv Ophthalmol 1993; 141–148, 38 Suppl
- Donshik P C, Pearlman D, Pinnas J, Raizman M B, Tauber J, Tinkelman D, Walters T R. Efficacy and safety of ketorolac tromethamine 0.5% and levocabastine 0.05%: a multicenter comparison in patients with seasonal allergic conjunctivitis. Adv Ther. 2000; 17(2)94–102
- Laibovitz R A, Koester J, Schaich L, Reaves T A. Safety and efficacy of diclofenac sodium 0.1% ophthalmic solution in acute seasonal allergic conjunctivitis. J Ocul Pharmacol Therapeu 1995; 11(3)361–368
- Sharma A, Gupta R, Ram J, Gupta A. Topical ketorolac 0.5% solution for the treatment of vernal keratoconjunctivitis. Indian J Ophthalmol 1997; 45(3)177–180
- Sud R N, Greval R S, Bajwa R S. Topical flurbiprofen therapy in vernal keratoconjunctivitis. Indian J Med Sci 1995; 49(9)205–209
- Tinkelman D G, Rupp G, Kaufman H, Pugely J, Schultz N. Double-masked, paired-comparison clinical study of ketorolac tromethamine 0.5% ophthalmic solution compared with placebo eyedrops in the treatment of seasonal allergic conjunctivitis. Surv Ophthalmol 1993; 133–140, 38 Suppl
- Yaylali V, Demirlenk I, Tatlipinar S, Ozbay D, Esme A, Yildirim C, Ozden S. Comparative study of 0.1% olopatadine hydrochloride and 0.5% ketorolac tromethamine in the treatment of seasonal allergic conjunctivitis. Acta Ophthalmol Scand 2003; 81(4)378–382
- Ciprandi G, Buscaglia S, Cerqueti M P, Sacca S, Tosca M, Canonica G W. Topical anti-inflammatory drugs in the treatment of allergic pollinosic conjunctivitis: a comparative double-blind study. J InvestigationAllergology Clinl Immunol 1992; 2(5)248–252
- Sharir M. Exacerbation of asthma by topical diclofenac. Arch Ophthalmol 1997; 115(2)294–295
- Sheehan G J, Kutzner M R, Chin W D. Acute asthma attack due to ophthalmic indomethacin. Ann InternMed 1989; 111(4)337–338
- Uchio E, Kadonosono K. Acute asthma attack caused by ophthalmic application of antiallergic agents. Japan J Ophthalmol 2004; 48(5)475–477